Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Jasper Ward WASHINGTON, June 26 (Reuters) - The United States has seized nearly 400…
By Jasper Ward WASHINGTON, June 26 (Reuters) - The United States has seized nearly 400…
By Jasper Ward WASHINGTON, June 26 (Reuters) - The United States has seized nearly 400…
Berlin (dpa) - People react differently to heat, with some fine even as temperatures soar,…
Mumbai (Maharashtra) [India], June 26: In a significant move aimed at strengthening environmental governance and…
Jamshedpur (Jharkhand) [India], June 26: XLRI – Xavier School of Management has been awarded the…